explore -WSS

explore

author：comprehensive 2025-08-12 06:45:19 - browse：22

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Telehealth for opioid use disorder is lifesaving

WSS

Vertex Pharmaceuticals may move headquarters in Boston

The Readout: Lenmeldy, GLP

Why the world’s most expensive drug might be worth the price

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Acelyrin, a rare IPO success, stumbles in its first big test

Telehealth for opioid use disorder is lifesaving

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

At least 13 dead in Texas as scorching temps continue

Washington mulls new rules to avert another Change Healthcare

Duchenne breakthrough therapy leaves behind pioneering families

WATCH: Why do bright lights make us see spots?

23andMe had bad news about my health. I wish a person had delivered it

Abortion pill Supreme Court ruling could impact entire drug industry

The high cost of giving birth even with insurance

Will the IRA bring competition to the biologics market?

Cancer drug shortages should be causing more outrage

Roche subsidiary Foundation Medicine opens new headquarters

knowledge

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Long Covid needs a new name — and a new frame

FDA proposes changes to key medical devices approval pathway

Popular nasal decongestant doesn't actually relieve congestion

How medical schools plan to diversify without affirmative action

States should stop sabotaging methadone treatment reform

focus

knowledge

focus

hotspot